Lupin Ltd operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Lupin Ltd with three other
pharmaceutical manufacturers in Asia:
Green Cross Holdings Corporation
of South Korea
sales of 1.35 trillion Korean Won [US$1.18 billion]
Kangmei Pharmaceutical Co Ltd
(21.61 billion Chinese Renmimbi [US$3.14 billion]
of which 87%
was Medicine), and
Hisamitsu Pharmaceutical Co Inc
based in Japan
(161.85 billion Japanese Yen [US$1.49 billion]
of which 100%
Lupin Ltd reported sales of 142.08 billion Indian Rupees (US$2.20 billion)
March of 2016.
increase of 11.3%
versus 2015, when the company's sales were 127.70 billion Indian Rupees.
Sales at Lupin Ltd have increased during each of the previous five years
(and since 2011, sales have increased a total of 149%).